Pioneering Novel Genetic Medicines for Cardiomyopathies
Our Mission
At Nuevocor, our mission is to revolutionize the treatment of untreatable cardiomyopathies by embracing a mechanobiology-centered approach.
These conditions represent a pressing medical challenge, striking individuals at a relatively young age and leads to heart failure. Presently, the only recourse for these patients is a costly and often elusive cardiac transplant.
About Us
With operations in both the United States and Singapore, Nuevocor focuses on treating heart conditions known as genetic cardiomyopathies by addressing their underlying mechanical defects.
Nuevocor’s lead program NVC-001 is a genetic medicine to treat patients suffering from lamin-related dilated cardiomyopathy.
News
24 January 2025
Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors
SINGAPORE and PHILADELPHIA, Jan. 24, 2025 /PRNewswire/ -- Nuevocor, an IND-stage biotechnology company dedicated to developing functional cures to treat cardiomyopathies with aberrant mechanobiology, today announces the appointment of Dr. Andreas Wallnöfer as Chairman of Nuevocor's Board of Directors.
15 October 2024
Nuevocor to present at European Society for Gene and Cell Therapy (ESGCT) 31st Annual Congress 2024
We are pleased to share that Dr Yann Chong Tan, Chief Executive Officer and co-founder of Nuevocor, will be delivering an oral presentation titled “NVC-001 – an AAV gene therapy for LMNA-related dilated cardiomyopathy” at the European Society for Gene and Cell Therapy 31st Annual Congress on 22 – 25 October 2024, La Nuvola, Rome. The presentation is scheduled on 24 October 2024 during Session 7c: Cardio and Muscular between 9.00am to 11.00am.